Articles
Page 13 of 19
-
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P316
-
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P314 -
Economic modeling of the combined effects of HIV disease, heart disease and lipoatrophy based on ACTG 5142 trial data
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P312 -
An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UK
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P310 -
96 weeks pharmacoeconomic outcome of lopinavir/r monotherapy as maintenance strategy in HIV+ patients with suppressed viral load. OK04-PharmECO analysis
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P308 -
Outcome of chronic hepatitis delta in patients with and without HIV infection in the HAART era
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P284 -
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P282 -
Abstract withdrawn
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P280 -
Efficacy of shorter duration HCV treatment in injection drug users (IDUs)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P278 -
Continuing evidence to support the role of early kinetic monitoring in predicting sustained viral response for HIV/HCV co-infected patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P276 -
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P245 -
Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P243 -
The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P239 -
Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P237 -
Measurement of 3-methylhistidine in spot urine from HIV-infected persons: an alternative screening method for muscle protein degradation to serum CK
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P210 -
Effect of hemolysis on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a 2-year analysis
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P208 -
Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P206 -
Influence of gender in predicting CCR5 coreceptor usage
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P202 -
Depression in HIV patients is associated with low adherence: a cross-sectional study among HIV patients in Denmark
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P174 -
Challenges to adherence among HIV-positive patients on antiretroviral therapy in Lagos, Nigeria
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P172 -
Adherence with lopinavir/ritonavir (LPV/r) tablet and SoftGel (SGC) capsule based antiretroviral regimens and predictors of early treatment compliance
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P170 -
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P168 -
Relationship between different types of non-adherence behaviour and virological response in unselected HIV-positive cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P166 -
Hepatic safety of tipranavir/ritonavir (TPV/r)-based antiretroviral therapy: effect of hepatitis virus co-infection and baseline liver fibrosis
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P141 -
Risk factors for advanced liver fibrosis in HIV-infected individuals: role of the metabolic syndrome
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P137 -
Screening for liver fibrosis in HIV-mono-infected patients with increased ALT comparing FibroScan with FIB-4
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P135 -
Evaluation of kidney toxicity in HIV patients with tenofovir-based regimen: the role of boosted protease inhibitor in real clinical setting
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P133 -
A central body fat distribution is related to increased renal arterial resistance index and renal function impairment in HIV-1 infected patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P131 -
A cross-sectional comparison of renal function in patients on stable abacavir (ABC) or tenofovir (TDF) containing therapy
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P129 -
Prevalence of cardiovascular risk factors (CRF) and metabolic syndrome (MS) in a cohort of HIV-infected patients in southern Spain. PREGO study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P102 -
Contribution of antiretroviral therapy, cardiovascular risk factors and constituents of metabolic syndrome to insulin resistance(IR) in HIV
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P100 -
Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status?
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P83 -
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P81 -
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P77 -
Use of lopinavir/ritonavir in first-line therapy or second-line therapy: 48-week results from the German prospective STAR cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P75 -
Use of traditional complementary and alternative medicine (TCAM) by HIV patients prior to initiating ART in KwaZulu-Natal, South Africa
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P73 -
Positive predictive factors in HIV-1 patients treated with enfuvirtide plus an OB that include an active boosted PI. Preliminary FastFuz study results
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P44 -
Exposition and sequencing to antiretrovirals in HIV-1 patients with triple-class antiretroviral failure, and harbouring protease resistance mutations
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P42 -
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P40 -
Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P38 -
Antiretroviral treatment use and HIV-RNA suppression rates for 877 European patients in the etravirine expanded access programme
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P36 -
O324 HIV, immune deficiency and malignancy
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O34 -
O322 Bone disease and HIV – together for the long term
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O32 -
O312 Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O28 -
Evaluating affordable screening markers to detect HIV-1-infected Ugandan adults with CD4 counts of less than 200 cells/mul
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P11 -
Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P9 -
O124 Efavirenz and rifampicin in the South African context: is there a need to dose increase efavirenz with concurrent rifampicin therapy?
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O9 -
Similar virological response rates for ART-naïve subjects starting KVX + LPV/r or TVD+ LPV/r. Data from the prospective observational STAR cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P7 -
Effects of NRTI backbone on HIV RNA, CD4 counts and lipids for first-line boosted PI-based HAART: meta-analysis of 12 clinical trials in 4,896 patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P5 -
Impact of antiretroviral dosing and daily pill burden on viral rebound rates in naive patients receiving a tenofovir-based regimen
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P3